NASDAQ:NEUP

Neuphoria Therapeutics Q4 2025 Earnings Results & Report

Neuphoria Therapeutics logo
$2.29 +0.02 (+0.88%)
Closing price 03:59 PM Eastern
Extended Trading
$2.28 -0.01 (-0.44%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Neuphoria Therapeutics missed analyst earnings expectations in its Q4 2025 results, released September 29, 2025. The company reported EPS of -$5.79 versus the -$0.56 consensus estimate, while revenue was -$13.27 thousand.

Earnings Announcement Details

Quarter
Q4 2025
Time
Before Market Opens
Conference Call
8:00 AM ET

Neuphoria Therapeutics EPS Results

Actual EPS
-$5.79
Consensus EPS
-$0.56
Beat/Miss
Missed by -$5.23
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 6 quarters

Neuphoria Therapeutics Revenue Results

Actual Revenue
-$13.27 thousand
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Neuphoria Therapeutics Q4 2025 Earnings FAQ

Neuphoria Therapeutics (NASDAQ:NEUP) reported earnings of -$5.79 per share for Q4 2025, missing the consensus estimate of -$0.56. The report was announced on Monday, September 29, 2025.

Neuphoria Therapeutics reported revenue of -$13.27 thousand for Q4 2025.

Neuphoria Therapeutics Earnings Headlines

Your Social Security check is scheduled for a 22% cut
The U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt death spiral. Interest payments alone now top a trillion dollars a year. The Social Security trust fund is projected to run dry by 2032, which could trigger an automatic 22% cut to benefits. Between 2020 and 2022, the Fed expanded the money supply by 41%. A free 27 page report breaks down these numbers in plain English, including what central banks have been doing with gold.tc pixel
Neuphoria Therapeutics Inc Ordinary Shares NEUP
Neuphoria Therapeutics Inc (NEUP)
See More Neuphoria Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Neuphoria Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Neuphoria Therapeutics and other key companies, straight to your email.

About Neuphoria Therapeutics

Neuphoria Therapeutics (NASDAQ:NEUP), Inc. is a clinical-stage biopharmaceutical company focused on developing investigational treatments for neurological and psychiatric conditions.

The company’s work centers on advancing drug candidates intended to address needs in brain health. Its products remain in development rather than being established, marketed therapies.

Publicly available information about Neuphoria’s specific development programs, operating geographies and leadership is limited, so no additional details are included here.

View Neuphoria Therapeutics Profile